Could this treatment provide a new avenue for chronic pain in PTSD patients?
A recent Phase 2 clinical trial sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) has investigated the potential of methylenedioxymethamphetamine (MDMA)-assisted therapy in treating chronic pain among patients with severe post-traumatic stress disorder (PTSD). Utilizing a subset of participants, the trial’s findings illustrate that MDMA therapy led to notable reductions in chronic pain scores for medium- and high-pain subgroups, bringing forth implications for novel treatments in pain management for PTSD patients.
- The study included 33 participants, with an 84% prevalence of pain; 75% reported disability associated with their pain.
- Assessment used the Chronic Pain Grade Scale (CPGS) before and after therapy sessions.
- Participants underwent three 8-hour MDMA sessions along with non-drug 90-minute sessions.
- Doses of MDMA ranged from 80 mg to 120 mg; significant reduction in pain intensity and disability scores were observed.
- The study emphasized the urgent need for new treatments for chronic pain, frequently co-occurring with PTSD.
- Trial results must be considered preliminary and primarily hypothesis generating.
- Although the data is limited, the results suggest that MDMA-assisted therapy may be a promising method for reducing chronic pain and related disability among individuals with PTSD, warranting further investigation.
Pain Medicine Latest Posts
- Images in Clinical Medicine: Quadriceps Tendon Ruptures
- 9 Stretches for Sciatica Pain Relief
- FDA Approves Nonopioid Combination Therapy for Postoperative Pain
- TikTok Users Say Hot Foot Baths Relieve Migraine Pain. But Does It Actually Work?
Did You Know?
According to the World Health Organization, an estimated 3.6% of the global population has suffered from PTSD at some point in their lives, emphasizing the importance of innovative approaches to treatment and management.